Form 4: Indaptus Therapeutics CEO Acquires Shares and Warrants in Recent Transaction

Indaptus Therapeutics CEO Jeffrey Meckler acquired 84,932 shares of common stock and an equal number of warrants at a price of $1.825 per share on August 8, 2024.

Summary

• On August 8, 2024, Jeffrey A. Meckler, CEO and Director of Indaptus Therapeutics, Inc., acquired 84,932 shares of common stock and 84,932 warrants of Indaptus Therapeutics.
• The purchase price was $1.825 per share.
• The aggregate purchase price for the shares and warrants was $155,000.90.
• Following the transaction, Meckler directly owns 160,306 shares of common stock.
• The warrants are exercisable at $1.70 and expire on August 8, 2029.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard insider transaction. The CEO's purchase is a positive signal, but it's not overwhelmingly significant.

Positives

• The CEO's purchase of shares and warrants could be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

Insider transactions are closely monitored by investors as they can provide insights into management's perspective on the company's value and future performance. This transaction is a routine disclosure required by the SEC.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment.

Key Dates

Keywords

Indaptus Therapeutics, Jeffrey Meckler, Insider Trading, Form 4, Common Stock, Warrants, INDP